Quantification of the antigen density activation threshold for targeted immunotherapeutics

The number of antibody-targeted I-O therapeutics in development is growing Y-o-Y, yet there persists a lack of in vitro systems to interrogate the efficacy and safety of these modalities. Explore innovations in technology from RoukenBio that provide an in vitro cell-based platform to allow the expression of one, or two, target antigens over a range of biologically relevant levels, allowing the determination of the precise antigen density activation thresholds of targeted candidate immunotherapies.